基于肽的副结核分枝杆菌疫苗研究
本研究探讨基于35 kDa膜肽(MMP)的疫苗对抗副结核分枝杆菌(Map)的可行性。体外疫苗接种实验显示,MMP单独或整合入PLGA/MPLA纳米颗粒载体均可诱导CD8细胞毒性T细胞(CTL),且载体整合增强了CTL杀伤胞内细菌的能力。结果表明MMP整合入PLGA/MPLA纳米颗粒载体是开发Johne病疫苗的可能途径之一。
要点
- MMP单独或整合入PLGA/MPLA纳米颗粒均可诱导CD8 CTL。
- 整合入纳米颗粒载体增强了CD8 CTL杀伤胞内细菌的能力。
- MMP整合入PLGA/MPLA纳米颗粒是开发Johne病疫苗的可能途径。
核心结论
- MMP整合入PLGA/MPLA纳米颗粒载体是开发基于MMP的Johne病疫苗的可能途径之一。
研究设计与样本
- 体外疫苗接种研究,使用MMP单独及整合入由聚(D,L-丙交酯-co-乙交酯)和单磷酰脂质A(PLGA/MPLA)组成的纳米颗粒载体。
主要发现
- 用MMP单独或整合入PLGA/MPLA载体脉冲的经典和单核细胞衍生树突状细胞(cDC和MoDC)均能诱导CD8 CTL。
- 将MMP整合入纳米颗粒载体增强了CD8 CTL杀伤胞内细菌的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent efforts to develop a live attenuated vaccine against Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease (JD), revealed relA is important in Map virulence. Deletion of the relA gene impairs the ability of Map to establish a persistent infection. Analysis of the basis for this observation revealed infection with a relA deletion mutant (ΔrelA) elicits development of cytotoxic CD8 T cells (CTL) with the ability to kill intracellular bacteria. Further analysis of the recall response elicited by ΔrelA vaccination showed a 35 kDa membrane peptide (MMP) is one of the targets of the immune response, suggesting it might be possible to develop a peptide-based vaccine based on MMP. To explore this possibility, ex vivo vaccination studies were conducted with MMP alone and incorporated into a nanoparticle (NP) vector comprised of poly (D, L-lactide-co-glycolide) and monophosphoryl lipid A (PLGA/MPLA). As reported, ex vivo vaccination studies showed CD8 CTL were elicited with classic and monocyte derived dendritic cells (cDC and MoDC) pulsed with MMP alone and incorporated into a PGLA/MPLA vector. Incorporation of MMP into a NP vector enhanced the ability of CD8 CTL to kill intracellular bacteria. The findings indicate incorporation of MMP into a PGLA/MPLA nanoparticle vector is one of the possible ways to develop a MMP based vaccine for Johne's disease.
引用
- Abdellrazeq GS, Elnaggar MM, Bannantine JP, et al. A peptide-based vaccine for Mycobacterium avium subspecies paratuberculosis. Vaccine. 2019. PMID: 31003915. doi:10.1016/j.vaccine.2019.04.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。